[go: up one dir, main page]

ATE288765T1 - Polypeptidzusammensetzungen mit verbesserter stabilität - Google Patents

Polypeptidzusammensetzungen mit verbesserter stabilität

Info

Publication number
ATE288765T1
ATE288765T1 AT00983782T AT00983782T ATE288765T1 AT E288765 T1 ATE288765 T1 AT E288765T1 AT 00983782 T AT00983782 T AT 00983782T AT 00983782 T AT00983782 T AT 00983782T AT E288765 T1 ATE288765 T1 AT E288765T1
Authority
AT
Austria
Prior art keywords
glycerin
compositions
polypeptide
chemical stability
improved stability
Prior art date
Application number
AT00983782T
Other languages
English (en)
Inventor
Michael Rosario Defelippis
Michael Allen Dobbins
Alby David Sharknas
Alex Mark Prokai
Joseph Vincent Jun Rinella
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27341882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE288765(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP37720899A external-priority patent/JP2001181203A/ja
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE288765T1 publication Critical patent/ATE288765T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT00983782T 1999-12-16 2000-12-05 Polypeptidzusammensetzungen mit verbesserter stabilität ATE288765T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17113599P 1999-12-16 1999-12-16
JP37720899A JP2001181203A (ja) 1999-12-16 1999-12-28 安定性が改良されたポリペプチド組成物
US18103000P 2000-02-08 2000-02-08
PCT/US2000/032421 WO2001043762A2 (en) 1999-12-16 2000-12-05 Polypeptide compositions with improved stability

Publications (1)

Publication Number Publication Date
ATE288765T1 true ATE288765T1 (de) 2005-02-15

Family

ID=27341882

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983782T ATE288765T1 (de) 1999-12-16 2000-12-05 Polypeptidzusammensetzungen mit verbesserter stabilität

Country Status (15)

Country Link
EP (1) EP1242121B1 (de)
JP (1) JP2003523972A (de)
CN (1) CN1409640A (de)
AT (1) ATE288765T1 (de)
AU (1) AU777570B2 (de)
BR (1) BR0016334A (de)
CA (1) CA2394213A1 (de)
DE (2) DE60018105T2 (de)
DK (1) DK200000375U1 (de)
EA (1) EA004631B1 (de)
ES (1) ES2236010T3 (de)
IL (1) IL150129A0 (de)
PL (1) PL355378A1 (de)
PT (1) PT1242121E (de)
WO (1) WO2001043762A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP1567127A4 (de) * 2002-10-17 2007-02-21 Alkermes Inc Verfahren zur modifizierung des freisetzungsprofiles von zusammensetzungen mit verzögerter freisetzung
JPWO2004037293A1 (ja) * 2002-10-22 2006-02-23 大日本住友製薬株式会社 安定化組成物
CN102940879B (zh) 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
JP4167288B2 (ja) 2003-11-20 2008-10-15 ソルヴェイ（ソシエテ アノニム） グリセロールからジクロロプロパノールを製造するための方法であって、該グリセロールが最終的にバイオディーゼルの製造における動物性脂肪の転化から生じる方法
PL1687019T3 (pl) 2003-11-20 2018-05-30 Novo Nordisk A/S Formulacje peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniach do wstrzykiwań
ES2442223T3 (es) 2004-08-31 2014-02-10 Novo Nordisk A/S Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
EP1817048B1 (de) 2004-11-12 2014-02-12 Novo Nordisk A/S Stabile formulierungen insulinoptropischer peptide
DK1884507T3 (da) * 2006-07-27 2010-08-16 Cognis Ip Man Gmbh Fremgangsmåde til fremstilling af glycerol
TWI478875B (zh) 2008-01-31 2015-04-01 Solvay 使水性組成物中之有機物質降解之方法
HUE032287T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
FR2935968B1 (fr) 2008-09-12 2010-09-10 Solvay Procede pour la purification de chlorure d'hydrogene
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
HUE038147T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland GLP-1 agonistát, inzulint és metionint tartalmazó gyógyászati készítmény
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2433651B1 (de) 2010-09-03 2013-03-20 Aug. Hedinger GmbH & Co. KG Bestimmungsmethode für Aldehyde und Ketone in Glycerin
JP6049087B2 (ja) 2010-09-30 2016-12-21 ソルヴェイ（ソシエテ アノニム） 天然起源のエピクロロヒドリンの誘導体
US9097692B2 (en) 2010-10-01 2015-08-04 Aug. Hedinger Gmbh & Co. Kg Method for quantitatively determining impurities in glycerin
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2018109162A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
CN118903385A (zh) 2017-08-24 2024-11-08 诺和诺德股份有限公司 Glp-1组合物及其用途
JP2023505190A (ja) 2019-12-06 2023-02-08 ドクター メアリー モリス アンド アソシエイツ リミテッド ライアビリティ カンパニー １型糖尿病の治療および予防のための方法および組成物
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物
WO2024081659A1 (en) * 2022-10-13 2024-04-18 Archer Daniels Midland Company Purification of glycerin as excipient in parenteral pharmaceutical applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228094B1 (en) * 1996-06-20 2012-10-29 Novo Nordisk As Insulin preparations containing nacl

Also Published As

Publication number Publication date
IL150129A0 (en) 2002-12-01
WO2001043762A2 (en) 2001-06-21
DE60018105T2 (de) 2005-12-29
EP1242121A2 (de) 2002-09-25
DK200000375U1 (da) 2001-03-16
ES2236010T3 (es) 2005-07-16
CA2394213A1 (en) 2001-06-21
PT1242121E (pt) 2005-05-31
BR0016334A (pt) 2002-09-10
DE20021079U1 (de) 2001-03-22
WO2001043762A3 (en) 2002-01-10
AU777570B2 (en) 2004-10-21
PL355378A1 (en) 2004-04-19
EA004631B1 (ru) 2004-06-24
EP1242121B1 (de) 2005-02-09
DE60018105D1 (de) 2005-03-17
CN1409640A (zh) 2003-04-09
JP2003523972A (ja) 2003-08-12
EA200200684A1 (ru) 2003-02-27
AU2049301A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
DE60018105D1 (de) Polypeptidzusammensetzungen mit verbesserter stabilität
TR200402703T4 (tr) Çözünür CTLA4 mutantları ve bunların kullanımı.
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
TR199901238T2 (xx) Asalak �ld�r�c� olarak 3-thiokarbamoylpirazol t�revleri.
SE0002102D0 (sv) Chemical compound
EA200201096A1 (ru) СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
ATE384119T1 (de) Isoprenoidproduktion
PT1109812E (pt) Pirrolobenzodiazepinas
BR0009421A (pt) Inibidores de ligação lfa-1 aos icams e uso dos mesmos
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
RS51478B (sr) Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove kombinacije lekova
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
TR200100273T2 (tr) Enjeksiyon için parasetamol bazlı farmasötik bileşim.
BR9813810B1 (pt) surfactante baseado em um orto éster, a sua preparação e o seu uso.
TR200501541T2 (tr) Leu-hirudinin e.coli ile kültür ortamında ayrışarak üretilmesinin sinyal sekansları
WO2002021133A3 (en) Methods of detecting cancer based on prostasin
SE1212311T3 (de)
ES2186596T1 (es) Uso de inhibidores de il-18.
ES2175899T3 (es) Procedimiento para la preparacion de derivados de piridindicarboxilato.
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
SE9802507D0 (sv) Novel salts
FR2843116B1 (fr) Utilisation d'une structure a base de poly(dimethylcetene) et objets comprenant cette structure
AU2001218083A1 (en) Ace inhibitor-vasopressin antagonist combinations
TR200102815T1 (tr) Displazili dokunun tespiti için kullanılacak in vivo lekeleme bileşik ve metodları.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242121

Country of ref document: EP

RZN Patent revoked
RZN Patent revoked